INTRODUCTION
Neisseria meningitidis is the bacterium that causes meningococcal disease, one of the leading sources of community-acquired sepsis and meningitis among children. Both sporadic and epidemic disease can occur, and a large number of individuals can become infected within a short period of time. The manner by which meningococcal disease strikes previously healthy individuals, with a rapid progressive illness and even death, has made this a disease of public health concern. In this article, we review the basic microbiology, epidemiology, clinical presentation, treatment, and prevention of meningococcal disease.
MICROBIOLOGY
N meningitidis is an aerobic, nonmotile Gram-negative diplococcus bacterium. It is considered a fastidious organism, with specific temperature and carbon dioxide requirements, and grows best on chocolate or blood agar. All Neisseria species (including Neisseria gonorrhoeae) are catalase-and oxidase-positive, although individual species can be differentiated based on biochemical properties. For AUTHOR DISCLOSURE Dr Vaz has disclosed no financial relationships relevant to this article. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device. example, N meningitidis can produce acid from glucose and maltose, but N gonorrhoeae is unable to utilize maltose.
ABBREVIATIONS
(1) (2) Humans are the only known reservoir for this bacterium. The nasopharynx may be asymptomatically colonized via aerosolized droplets containing meningococci. Colonization provides the source by which organisms are spread. Most of those who are colonized with meningococcus do not get sick. Disease is caused when bacteria invade epithelia and enter the bloodstream, resulting in systemic disease. (3)(4) Bacterial virulence factors enable meningococci to survive and invade the human host. Those bacteria capable of invasion are encapsulated. The capsule is characterized by a specific serogroup that is antigenically and chemically distinct. The polysaccharide capsule serves as a defense barrier by inhibiting host phagocytosis and complement-mediated lysis. Twelve capsule serogroups have been identified: A, B, C, H, I, K, L, W135, X, Y, Z, and 29E. (2)(5)(6) Those commonly associated with disease are: A, B, C, Y, W135, X, and occasionally L and Z. Within each group, subtypes and genotypes vary in their virulence and the severity of disease that they cause. (7)(8) Other bacterial virulence factors play a role in attaching to cells and eliciting the host response to infection. The pili and opacity proteins on the outer membrane are instrumental in attachment, leading to colonization and invasion. N meningitidis also contains lipooligosaccharide (LOS) molecules in the outer membrane wall of the cell envelope. LOS is similar in function to the lipopolysaccharide endotoxin in other Gram-negative bacteria but lacks the O-antigenic repeats. The release of the LOS endotoxin triggers a cascade of inflammation that produces the features of septic shock that are seen in patients with meningococcemia. (9)(10) Higher concentrations of meningococcal LOS are found in severe meningococcal disease and correlate with mortality. (11)
EPIDEMIOLOGY
The annual incidence of meningococcal disease in the United States has traditionally varied from 0.3 to 1.5 cases per 100,000 persons. (12)(13) The United States is currently experiencing a historic low in meningococcal disease. (14) In 2014, there were 426 total cases of meningococcal disease reported, with an incidence rate of 0.14 cases per 100,000 persons. (15) This decrease preceded the introduction of meningococcal quadrivalent conjugate vaccines into the immunization schedule and may be due to natural immunity within the population, changes in behavioral risk factors (such as smoking), and decreased virulence of circulating meningococcal strains. (16) (44) Perhaps due to the bacterium's ability to infect healthy young adults, attention has been paid to adolescent risk factors in particular. Epidemiologic studies document that carriage rates rise in the first months of college arrival, and risk of disease is highest among first-year students living in dormitories. (42) Despite this, there is not an increase in the incidence of meningococcal infection among college students compared with age-matched controls, although among affected college students, the rates of illness were higher among freshman and for students residing on campus. (21)(41)(45)(46) Vaccination of college freshmen with quadrivalent vaccine is recommended by the Advisory Committee on Immunization Practices (ACIP) and has been a focus for primary prevention of disease.
CLINICAL PRESENTATION
In the era of vaccination for Haemophilus influenzae and Streptococcus pneumoniae, meningococcal disease should be considered for a child who presents with acute signs of sepsis or meningitis. The incubation period is between 1 and 10 days (often <4 days) and believed to be within 48 to 72 hours of new colonization by an invasive strain. Clinical presentation of N meningitidis infection can vary, ranging from fever to meningitis or sepsis and fulminant disease with death within hours. (19) At the onset, patients can present with fever and signs of an upper respiratory tract infection without toxicity. Myalgia may be intense and the presentation may be mistaken for influenza. (47) Median time from onset of symptoms to hospital admission was estimated at less than 22 hours in 1 study. (47) Approximately 50% of cases result only in meningitis, and the remainder are characterized by either sepsis or both sepsis and meningitis. (15)(19) (29) As the more common clinical presentation, meningococcal meningitis itself is indistinguishable from acute meningitis caused by other pathogens. In younger children, meningeal signs may be less apparent, but irritability is often present. Seizures may also occur but are less common than seen with H influenzae and S pneumoniae infections. (48 The rash in meningococcal disease, a distinguishing feature, begins as macules, papules, or urticaria but becomes petechial within hours after initial sick symptoms begin. It is important to note that only 2% to 11% of children who present with a petechial rash have meningococcal disease. (53) Infection with other viruses, such as enterovirus, Epstein-Barr virus, cytomegalovirus, and measles, may demonstrate a similar-appearing rash. (19)(47)
Less common manifestations of meningococcal infection include pneumonia, septic arthritis, epiglottitis, osteomyelitis, urethritis, and pericarditis. (19)(54)(55)(56)(57) Meningococcal conjunctivitis should be managed as invasive disease because topical therapy does not prevent invasion and secondary cases can occur. (58) Reactive complications, such as arthritis, vasculitis, and pericarditis, can occur a few days after treatment. These complications can be associated with fever and resolve spontaneously within 10 days. Symptomatic relief with nonsteroidal antiinflammatory drugs may be beneficial. (19)(59) Chronic meningococcemia is a rare form of meningococcal infection characterized by recurrent episodes of fever, rash, arthralgia, arthritis, and headache over weeks to months in association with bacteremia that clears without treatment. The patient is well between episodes. (60) Chronic meningococcemia may be more common in patients with immunodeficiency. (61) Predictors of poor outcome in meningococcal disease include young age, hypotension, leukopenia, thrombocytopenia, and altered mental status. (19)(62)(63) Sequelae associated with meningococcal disease occur in up to 20% of survivors, characterized by physical and neurologic disabilities, such as loss of digits or limb(s), skin scarring, deafness, or brain damage. (19)(29) Rates of severe neurologic sequelae, however, are comparably lower after meningitis due to N meningitidis than H influenzae or S pneumoniae. (50)(64) The current mortality rate from meningococcal disease is as high as 10% to 15% (50)(65)(66) but has been reported to be as low as 5%. (16)(67) A major determinant of a favorable outcome is the timing of antibiotic delivery and early correction of shock.
DIAGNOSIS
Because N meningitidis can be a component of normal nasopharyngeal flora, isolation of the pathogen from throat cultures alone is not helpful for diagnosis of clinical disease. Diagnosis is made through positive blood, cerebrospinal fluid (CSF), or skin lesion cultures or a culture from another sterile site. Culture is the gold standard for diagnosis and may be helpful in identifying drug resistance. (2)(68) For public health purposes, positive cultures are useful to classify cases, identify serogroup, and monitor for vaccine effectiveness. Blood cultures may be positive in 40% to 75% and CSF cultures in 90% of those not pretreated with antibiotics. Gram-stains of CSF are positive in 75% to 80% of untreated cases of meningitis and often demonstrate the classic-appearing Gram-negative diplococci. (69) (70) Antibiotics sterilize CSF within hours. (71) Use of other parameters, such as elevated CSF white blood cell (WBC) count (>22 CSF WBCs if younger than age 28 days and >15 CSF WBCs if older than age 28 days), elevated CSF protein (>120 g/dL), or low CSF glucose (<20 mg/dL) may be helpful to assess central nervous system involvement if cultures are pretreated or if there is a traumatic lumbar puncture. (72)(73) Skin biopsy and culture of the rash seen in meningococcemia shows endothelial necrosis, with meningococci present within the endothelium and thrombi. (74) Specific agglutination rapid diagnostic systems have been used in parts of the world in which the ability to obtain cultures is limited. (75) Real-time polymerase chain reaction (PCR) detection systems may be available for blood or CSF and help in pretreated cases, although the Centers for Disease Control and Prevention (CDC) continues to recommend culture as the gold standard for diagnosis. Molecular typing may also aid in tracking and linking cases in an outbreak. (76)(77)(78)(79) Based on the 2015 CDC case definitions, a confirmed case is a clinically compatible case in which N meningitidis is isolated by culture or PCR from a normally sterile site or purpuric lesions. Probable cases are those in which the presence of N meningitidis antigen by immunohistochemistry or latex agglutination of CSF is detected. Suspected cases are those in which a Gram-stain shows Gram-negative diplococci that are not yet identified obtained from a sterile site or there is clinical purpura fulminans but a negative blood culture. (30) TREATMENT Early diagnosis and optimal medical care are associated with improved outcomes. With antibiotics, mortality has been substantially reduced from a range of 70% to 85% to a range of 10% to 15%. (15)(25) Antibiotics should be immediately administered after blood specimens are obtained for culture in suspected meningococcal cases. The drug of choice for empirical treatment of meningococcal disease is a thirdgeneration cephalosporin, such as ceftriaxone or cefotaxime (Table 1) . (19)(42) Once susceptibilities are known, antibiotics can be changed to penicillin if the isolate has a minimum inhibitory concentration (MIC) of less than 0.1 mg/mL. (80) If the MIC is greater than this, a third-generation cephalosporin is preferred. (68)(81) Even if the bacterium is penicillinsusceptible, ceftriaxone is often used due to ease of administration, cost, and efficacy. Although ceftriaxone resistance may be seen with other Neisseria species, this is considered unlikely for N meningitidis. (82) If cultures were not obtained and treatment is presumptive based on clinical findings, treatment with ceftriaxone is continued. Care must be taken to dose antibiotics for the compartments that are infected. For patients with a history of anaphylaxis with penicillin or cephalosporin use, chloramphenicol can be used if available. Adverse effects of chloramphenicol include bone marrow suppression and in infants, gray syndrome. Meropenem is also an option, although the rate of cross-reactivity with penicillin is between 2% and 3%. (19)(80) Treatment duration is typically 5 to 7 days, and shorter treatment durations have been used in epidemic situations. (83) 
IMMUNITY
Most individuals develop natural immunity to meningococcus in the first 2 decades of life from exposure through nasopharyngeal colonization or cross-reactivity with other bacteria that have similar antigenic structures. (90) Susceptibility to invasion by a newly acquired strain of N meningitidis is associated with the absence of bactericidal antibody.
Antibody titers in infants are similar to maternal serum concentrations but decrease by age 6 months, correlating to the noted first peak incidence of meningococcal disease. In the absence of protective bactericidal titers, invasive disease is more likely. Developing sporadic meningococcal disease more than once is rare but possible due to infection with other serogroups; however, this would be highly suspicious for an underlying host immune defect. (91) Certain individuals may be at increased risk for meningococcal disease. These include children with human immunodeficiency virus (HIV), some children with partial T-cell defects (eg, DiGeorge syndrome, Wiskott-Aldrich syndrome, ataxia telangiectasia), those who have anatomic and functional asplenia (which are associated with impaired antibody production), and those who have complement deficiencies. (29) (92) Complement deficiency involving both the late (C5-C9) and early components (including C3, properdin, or factor H and D) of the complement system has been associated with increased susceptibility to meningococcal infection. The importance of complement-mediated killing in protection against meningococcal disease is highlighted by the high incidence of invasive meningococcal disease in persons with terminal complement deficiencies, which demonstrates that the membrane attack complex appears to be unique for killing meningococcus. Approximately 0.3% of those with meningococcal disease may have complement deficiency. (91) Recurrent attacks have been observed in those with terminal complement deficiency. (93)(94) Acquired complement deficiencies can result from inadequate production of complement components due to liver dysfunction, increased consumption of complement by autoimmune disease such as lupus, or increased excretion by protein-losing diseases. Patients receiving eculizumab therapy for atypical hemolytic-uremic syndrome are also at 
PREVENTION

Chemoprophylaxis
Clinicians must notify public health authorities at the onset of an index case to aid in the initiation of chemoprophylaxis and observation for secondary cases and outbreak prevention. (12) Chemoprophylaxis is indicated for close contacts irrespective of immunization status and should be administered as soon as possible after an exposure. The attack rate for close contacts of patients with sporadic disease is 4 in 1,000 exposed. (42) High-risk contacts who qualify for prophylaxis include household members (500-1,000 times the risk compared to general population). (29) In addition, for the 7 days before the onset of illness, high-risk contacts include those who slept in the same dwelling, those with prolonged contact (>8 hours) in close proximity (£3 feet) to the index case, those exposed to the patient's oral secretions (eg, kissing, sharing of food or glasses), and child care contacts or preschool contacts. Chemoprophylaxis is also recommended for health care workers exposed directly to patient's oral secretions who did not wear a surgical mask prior to the patient receiving 24 hours of appropriate antibiotic therapy. (40)(41)(42)(97) Chemoprophylaxis ideally should be administered within 24 hours of identification of the index patient. (98) Close follow-up evaluation is necessary due to the rapid onset of disease in linked cases. Secondary cases usually occur within 10 days of infection of the index case. Chemoprophylaxis administered greater than 14 days after exposure to the index case is of limited value and not recommended by the CDC. Mass chemoprophylaxis is generally not recommended, but this decision is directed by local public health authorities. (12) (78)(97) Untreated contacts can reinfect treated contacts, so it is important that all close contacts receive timely prophylaxis. Options for prophylaxis include rifampin, ceftriaxone, or ciprofloxacin (Table 1) . Rifampin is the only agent that has been studied widely, but there may be drug-drug interactions to consider. Adverse effects such as nausea and diarrhea can occur, and 4 doses are required for effective prophylaxis. Ceftriaxone in a single dose has been shown to be more than 97% effective in eradicating carriage after 1 to 2 weeks of follow-up assessment and is safe in pregnancy. (19) Ciprofloxacin also eradicates carriage in a single dose, although it cannot be used in pregnant women, and there may be concerns for resistance in parts of the United States. (99) Other adverse effects that should be discussed between the clinician and patient are rash, diarrhea, joint or tendon pain, confusion, or numbness or tingling of extremities. (100) Azithromycin may be used but is generally not recommended as a first-line agent. (42)(97)(101) Oral third-generation cephalosporin antibiotics are not recommended. (101) If a patient with meningococcal disease received therapy with an agent other than a parenteral third-generation cephalosporin, additional chemoprophylaxis with 1 of the antibiotics listed in Table 1 is required to reliably eradicate nasopharyngeal carriage before hospital discharge, thereby preventing transmission to close contacts. (19)(42) Vaccines Primary prevention through vaccination may reduce risk among certain groups and may be recommended by public health authorities during ongoing outbreaks. (12) Secondary prevention, when directed by public health, can be an adjunct to chemoprophylaxis when there is an outbreak caused by a serogroup contained in a vaccine. Some countries have implemented vaccine programs among high-risk groups based on the prevalent serogroups circulating. Specific vaccines are available with indications for administration that vary based on national guidelines. (102) In the United States, there are 3 vaccines for the A, C, Y, and W135 serogroups; 1 for serogroups C and Y that is combined with H influenzae type b vaccine; and 2 new vaccines for serogroup B. Vaccine development for serogroup B has lagged behind vaccine development for other serogroups due to poor immunogenicity of the B capsule, which contains a structure similar to human intracellular adhesion molecules. (103) In addition, the B serogroups are genetically diverse, making it challenging to create a vaccine that covers all circulating serogroup B strains.
Meningitis A, C, W135, and Y Vaccines
Vaccines have been developed for serogroups A, C, W135, and Y. They include a currently available polysaccharide vaccine first licensed in 1981 and the newer quadrivalent (ACWY) conjugated vaccines. (29) The polysaccharide vaccine has a shorter duration of protection based on antibody persistence, there are concerns for hyporesponsiveness with repeated doses, and the vaccine lacks efficacy in eradicating nasopharyngeal carriage. In contrast to the polysaccharide vaccine, the conjugated vaccines elicit a T-cell-dependent memory response that results in a more robust immune response.
ACIP recommends universal vaccination for adolescents with 1 of the 2 quadrivalent meningococcal vaccines licensed for protection against serogroups A, C, W135, and Y: MenACWY-D (Menactra Ò , Sanofi Pasteur, Swiftwater, PA) or MenACWY-CRM (Menveo Ò , Novartis Vaccines and Diagnostics, Inc, Cambridge, MA), ( Table 2 ). Antibody persistence studies indicate that circulating antibody declines 3 to 5 years after a single dose of MCV-4. The effectiveness, or the estimate of how well the vaccine works based on observational data, of quadrivalent vaccines is estimated at 80% to 85%. This range came from a 2005 through 2008 study among adolescents who received 1 dose of MenACWY-D, in whom there were 14 cases of breakthrough disease. (104) A booster at age 16 years is now recommended to ensure persistence of protective levels. (29)(105)106) No booster is required if the patient receives the vaccine at age 16 years or older. Vaccination coverage was estimated at 79% in 2014 among 13-to 17-year-old adolescents, but it lags behind tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis, vaccination in this age group, which nationally is approximately 87%. (107) Common adverse effects of the MCV-4 quadrivalent vaccines include fever (16.8%), headache (16.0%), injection site erythema (14.6%), and dizziness (13.4%), followed by syncope (10%). (29)(93) Meningitis A, C, W135, and Y Vaccines in High-risk Individuals
Vaccination is additionally recommended for high-risk individuals such as patients with persistent complement deficiencies; functional or anatomic asplenia, including sickle cell, HIV infection or recent eculizumab administration; with outbreak control; for travel to an epidemic area; and for those in high-risk occupational settings such as in microbiology laboratories and military recruit housing. (29)(108) For infants falling into 1 of these high-risk categories, vaccine options include HibMenCY-TT (MenHibrix Ò , GlaxoSmithKline, Research Triangle Park, NC) or MenACWY-CRM (Menveo Ò , Novartis Vaccines and Diagnostics, Inc, Cambridge, MA). HibMenCY-TTwas licensed in 2012 for ages 6 weeks through 18 months as a 4-dose series at 2, 4, and 6 months of age and once from age 12 to 15 months of age. This vaccine contains coverage for only meningococcal serogroups C and Y and is combined with vaccination for H influenzae type b. The child who received 1 of these vaccines still needs 1 of the quadrivalent (ACWY) vaccines when older. HibMenCY-TT is not sufficient for children living in or traveling to endemic regions because it does not contain serogroup A or W, which are significant serogroups in worldwide meningococcal disease.
MenACWY-D is licensed for use in ages 9 months through 55 years and is administered as a 2-dose primary series, 3 months apart. In young children at high risk of pneumococcal disease, such as the presence of asplenia, coadministration of MenACWY-D with pneumococcal 13-valent vaccine is not recommended due to concerns for pneumococcal hyporesponsiveness. Pneumococcal antibody responses to some serotypes in pneumococcal 13-valent vaccine were decreased when the vaccine was given at the same time as MenACWY-D. Because of this, if MenACWY-D is used in patients with anatomic or functional asplenia, administration is recommended after age 2 years and at least 4 weeks after the last pneumococcal dose. (93) Because the risk of pneumococcal disease in asplenic patients is higher than that for meningococcal disease, pneumococcal vaccination should be completed first in this particular group. (42) MenACWY-CRM is licensed for infants as a 4-dose series at 2, 4, 6, and 12 months of age and can be given through age 55 years. MenACWY-CRM can be given simultaneously with pneumococcal 13-valent vaccine or at any interval after receipt of pneumococcal 13-valent vaccines. (29)(109) For those older than 2 years who have completed pneumococcal vaccination, either MenACWY-D or MenACWY-CRM can be used for primary vaccination. The first booster dose for the ACWY vaccines in high-risk groups is every 5 years. The exception is for those who received the vaccine before age 7 years, when the first booster is given 3 years after the last meningococcal vaccine and every 5 years thereafter. (29) (94)(110)
Meningococcal B Vaccines
The new serogroup B meningitis vaccines underwent accelerated approval and were licensed in the United States in 2014 and 2015. They include MenB-FHbp (Trumenba Ò , Wyeth, Philadelphia, PA) and MenB-4C (Bexsero Ò , Novartis Vaccines and Diagnostics, Inc, Cambridge, MA). Both are approved for ages 10 through 55 years. MenB-4C is licensed in Europe, Canada, and Australia in addition to the United States; MenB-FHbp is only licensed in the United States. Both are recombinant protein vaccines. The primary differences between the 2 vaccines are the different subcapsular antigens and dosing regimens. MenB-FHbp is composed of 2 recombinant lipidated factor H-binding protein (FHbp) variants from N meningitidis serogroup B. MenB-FHbp is currently administered as a 3-dose series, with second and third doses given 2 and 6 months after the first, but it has recently gained approval for a 2-dose series.
(111) MenB-4C is composed of 4 distinct antigens, including a recombinant FHbp and other antigens. MenB-4C is a 2-dose series, with doses given 1 month apart. (94)(110) The tip cap of the syringe of MenB-4C may contain natural rubber latex. Although the risk of allergy is believed to be extremely low, precautions for possible allergic reactions should be taken when administering MenB-4C to latex-allergic patients. (112) Meningococcal B vaccines have been approved for use in high-risk patients age 10 years and older (Table 3) . (94)(110) ACIP has specifically detailed high-risk patients as those with asplenia, persistent complement deficiency, or eculizumab administration; those involved in outbreak settings; and microbiologists working with meningococcus in the laboratory. Under clinical discretion, teens and young adults (ages 16 through 23 years and preferably between ages 16 and 18 years) may also be vaccinated with a serogroup B meningococcal vaccine to provide short-term protection and maximize the likelihood for protection to last through MenACWY-D: 2 doses minimum 8 weeks apart Men B-4C: 2-dose series 1 month apart Men B 4C: 2-dose series 1 month apart MenB-4C: 2-dose series 1 month apart MenB-FHbp: 3-dose series, with second dose 2 months after the first and last dose 6 months after first dose MenB-FHbp: 3-dose series with second dose 2 months after the first and last dose 6 months after first dose MenB-FHbp: 3-dose series with second dose 2 months after the first and last dose 6 months after first dose a All high-risk children who receive MenACWY vaccines before age 7 years require a booster in 3 years and every 5 years after that. For high-risk children who receive their first meningococcal vaccines after age 7 years, boosters are every 5 years. In outbreak situations with serogroup C or Y for infants, Hib-MenCY-TT may be used. e MenACWY-CRM is certified halal for those who are traveling to Mecca. f Occupation exposure includes military recruits, laboratory workers. Indications for meningococcal vaccinations are evolving, particularly as new information is gathered on vaccine effectiveness and duration of protection as well as the evolving epidemiology of meningococcal disease. Parents should be advised of the recommendations set forth by the ACIP and the American Academy of Pediatrics, including for infants and adolescents. (94)(110)(113) Clinicians should counsel families on the unknown efficacy of these vaccines and review the risk in certain population groups, with vigilance to local community outbreaks. Clinicians should review the latest ACIP guidelines for the latest developments, changes to the vaccine schedule, and indications for administration.
CONCLUSION
Despite antibiotics and advances in the understanding and management of sepsis, N meningitis remains among the world's most feared infectious diseases. Prompt attention to particular risk groups, including those younger than age 1 year and adolescents, is important. Early initiation of antibiotics and supportive care is needed to mitigate the morbidity and mortality seen with this disease. Public health concerns due to the contagiousness of the disease and the ability to cause epidemic disease demonstrate the need for early identification of index patients and their contacts. The effect of new vaccines on disease distribution and incidence needs to be studied through postlicensure studies.
